Innate Pharma S.A. (IPHA) — 分析师展望 / 分析师共识目标价为. 基于 6 位分析师评级, 共识为 看涨 — 4 买入, 2 持有.
分析师共识目标价为 $5.00, 上涨空间为 206.7% 相对于当前价格 $1.63.
分析师预估 每股收益(EPS)为 $-0.36 和 营收为 $0.04B (下一财年).
每股收益(EPS)历史表现: 2024: 实际 $-0.61 vs 预期 $-0.36 (不及预期 -68.6%). 2025: 实际 $-0.53 vs 预期 $-0.55 (超预期 +2.8%). 分析师准确度: 78%.
IPHA 股票 — 12个月价格预测
$5.00
▲ +206.75% 上涨空间
平均目标价
Based on 6 Wall Street analysts offering 12-month price targets for Innate Pharma S.A., the price target is $5.00.
平均目标价相对最新价格 $1.63 变动 +206.75%。
IPHA 分析师评级
Buy
基于过去3个月内 6 位分析师对 Innate Pharma S.A. 的评级
EPS 预测 — IPHA
78%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual –$0.61
vs Est –$0.36
▼ 40.7% off
2025
Actual –$0.53
vs Est –$0.55
▲ 2.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
营收预测 — IPHA
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.013B
vs Est $0.040B
▼ 219.0% off
2025
Actual $0.003B
vs Est $0.015B
▼ 428.1% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
